ASM INTERNATIONAL N.V. ANNOUNCES THE AVAILABILITY OF THE 2022 AGM MATERIALS
Almere, the Netherlands
April 1, 2022
ASM International N.V. (Euronext Amsterdam: ASM) today announces that the information regarding the Annual General Meeting of Shareholders scheduled for May 16, 2022 (AGM), is now available on the Company's website. This information includes the convocation, the agenda and annexes thereto. The U.S. market proxy materials for holders of New York Registry Shares are also posted on our website. ASM also announces that Mr. Martin van Pernis will be succeeded by Mrs. Pauline van der Meer Mohr as chairperson of the Supervisory Board following the AGM.
The AGM will commence at 2:00 p.m. CET.
The AGM will be a hybrid meeting that can be attended in person or virtually by shareholders. As in previous years, our shareholders are also offered the possibility to exercise their voting rights by proxy and to follow the meeting through our live webcast.
In the event COVID-19 would require for health reasons that the meeting is to be held solely virtually and this would be accommodated by the Dutch legislation, then instructions will be made available on the website: www.asm.com.
The agenda for the AGM includes, amongst others, the proposals to appoint Mr. Hichem M’Saad as additional member of the Management Board, change the remuneration policy for the Management Board and Supervisory Board, re-appoint Mr. Marc de Jong as member of the Supervisory Board for another term of four years, approve the proposal to declare a regular dividend of €2.50 per common share, and approval of the annual accounts of 2021.
In accordance with applicable legal requirements in the Netherlands the record date for the AGM is April 18, 2022. The total number of issued shares in ASM International N.V. as per today amounts to 49,297,394 common shares. Considering the number of shares held in treasury as per today, amounting to 717,340 shares, the number of voting shares amounts to 48,580,054.
At the end of the AGM, Mr. van Pernis will retire from the Supervisory Board after 12 years, and the last year as chairperson. The Supervisory Board has appointed Mrs. Pauline van der Meer Mohr to become the chairperson of the Supervisory Board following the AGM.
Mr. van Pernis commented: “It was a real pleasure being part of the Supervisory Board over the last 12 years of which the last year as chairperson. The growth of the company during this time has been tremendous. I enjoyed being part of this and experiencing the progress on the technological front, and the enthusiasm and entrepreneurship of the Management Board and all employees. I wish the Management Board, Supervisory Board and all other colleagues all the best in the future. Last but not least I wish Pauline all the best as my successor as chairperson.”
Mrs. Pauline van der Meer Mohr commented: “First of all I would like to thank Martin for all of his contributions over the past 12 years. He has made many contributions with his extensive knowledge and experience. Furthermore, I am really looking forward to succeeding him as chairperson of the Supervisory Board and to continue with the entire Supervisory Board to contribute to the execution of the Growth through Innovation strategy. I wish Martin a well-deserved retirement.”
About ASM International
ASM International N.V., headquartered in Almere, the Netherlands, and its subsidiaries design and manufacture equipment and process solutions to produce semiconductor devices for wafer processing, and have facilities in the United States, Europe, and Asia. ASM International's common stock trades on the Euronext Amsterdam Stock Exchange (symbol ASM). For more information, visit ASM's website at www.asm.com.
Cautionary Note Regarding Forward-Looking Statements: All matters discussed in this press release, except for any historical data, are forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These include, but are not limited to, economic conditions and trends in the semiconductor industry generally and the timing of the industry cycles specifically, currency fluctuations, corporate transactions, financing and liquidity matters, the success of restructurings, the timing of significant orders, market acceptance of new products, competitive factors, litigation involving intellectual property, shareholders or other issues, commercial and economic disruption due to natural disasters, terrorist activity, armed conflict or political instability, changes in import/export regulations, epidemics and other risks indicated in the Company's reports and financial statements. The Company assumes no obligation nor intends to update or revise any forward-looking statements to reflect future developments or circumstances.
Investor and media contact:
T: +31 88 100 8500
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Zenas BioPharma Submits Investigational New Drug Application in China for ZB001 for the Treatment of Thyroid Eye Disease16.5.2022 00:00:00 CEST | Press release
WALTHAM, Mass. and SHANGHAI, China, May 15, 2022 (GLOBE NEWSWIRE) -- Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients in need around the world, today announced the submission of an investigational new drug (IND) application to the China National Medical Products Administration (NMPA) for the initiation of a Phase 1/2 clinical study of ZB001 for the treatment of Thyroid Eye Disease (TED). This study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ZB001. “The ZB001 IND submission to the NMPA marks a significant milestone for Zenas,” said Hua Mu, MD, PhD, Chief Executive Officer at Zenas. “There are currently no approved therapies for TED patients in China. Treatment options are limited and often involve high doses of steroids associated with serious side effects or surgical intervention. ZB001 has the potential to change the tre
Cool Company Ltd. – Mandatory Notification of Trade15.5.2022 14:52:24 CEST | Press release
EPS Ventures Ltd., close associate of Cyril Ducau, Chair of the Board of Cool Company Ltd. (the “Company”), has on 13 May 2022 acquired 38,419 shares in the Company at a price of NOK 84.63 per share. Following the transaction, EPS Ventures Ltd. holds a total of 15,038,419 shares in the Company, equivalent to 37.59% of the Company’s shares. Please see attached notification form in accordance with the Market Abuse Regulation article 19. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachment Primary insider notification form
Monthly information related to total number of voting rights and shares composing the share capital – April 30, 202213.5.2022 18:00:00 CEST | Press release
Monthly information related to total number of voting rights and shares composing the share capital –April 30, 2022. Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP) Website : www.erytech.com DateTotal of shares composing the share capitalTotal of brut(1) voting rights Total of net (2) voting rights December 31, 202131 018 55332 518 33932 515 839January 31, 202231 018 55332 518 33932 515 839February 28, 202231 018 55332 518 54732 516 047March 31, 202231 018 55332 518 54732 516 047April 30, 202231 018 55332 518 54732 516 047 (1) Gross voting rights number (or « theoretical » voting rights) is used as a basis for calculating the crossing of the threshold. In accordance with article 223-11 of general regulation of Autorité des Marchés Financiers, this number is calculated on t
Hövding ansöker om avnotering från Nasdaq First North Growth Market13.5.2022 17:45:00 CEST | Pressemelding
Styrelsen för Hövding Sverige AB (publ) (”Hövding”) har beslutat att ansöka om avnotering av Hövdings aktie från Nasdaq First North Growth Market (”First North”). Sista dag för handel på First North kommer att meddelas efter att Hövding erhållit bekräftelse om detta från Nasdaq. Fosielund Holding AB (”Fosielund”) offentliggjorde genom pressmeddelande den 13 januari 2022 ett offentligt budpliktserbjudande till aktieägarna i Hövding (”Erbjudandet”). Fosielund meddelande genom pressmeddelande den 16 februari 2022 att Fosielund (med närstående), efter redovisning av likvid i Erbjudandet, innehade 18 021 741 aktier motsvarande ca 65 procent av aktierna och rösterna. Den 8 april 2022 meddelade Fosielund genom pressmeddelande att de förvärvat en större post aktier i Hövding, varefter Fosielund innehade ca 88,7 procent av aktierna och rösterna samt en avsikt att förvärva ytterligare aktier. Den 4 maj 2022 meddelade Fosielund genom pressmeddelande att de förvärvat ytterligare aktier och att des
Fosielund Holding AB påkallar inlösen av återstående aktier i Hövding Sverige AB (publ)13.5.2022 17:45:00 CEST | Pressemelding
Pressmeddelande 13 maj 2022 Ej för offentliggörande, distribution eller publicering, varken direkt eller indirekt, i eller till Storbritannien, USA, Kanada, Japan, Australien, Hong Kong, Nya Zeeland, Schweiz, Sydafrika eller annan jurisdiktion där offentliggörande, distribution eller publicering skulle vara olaglig eller kräva registrering eller annan åtgärd. Fosielund Holding AB påkallar inlösen av återstående aktier i Hövding Sverige AB (publ) Fosielund Holding AB, org.nr 556140-5167, (”Fosielund Holding”) har idag till styrelsen för Hövding Sverige AB (publ), org.nr 556708-0303, (”Hövding”) påkallat inlösen av återstående aktier i Hövding från de övriga aktieägarna, i enlighet med 22 kap. 1 § aktiebolagslagen. Överenskommelse om inlösen av aktierna har inte kunnat träffas med samtliga övriga aktieägare. Fosielund Holding har därför begärt att tvisten avgörs av skiljemän i enlighet med 22 kap. 6 § aktiebolagslagen. För ytterligare information, vänligen kontakta: Joel Eklund, 040-6701